Liquidia (NASDAQ:LQDA) CFO Sells $539,354.24 in Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 18,938 shares of the stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $539,354.24. Following the sale, the chief financial officer directly owned 340,148 shares of the company’s stock, valued at $9,687,415.04. The trade was a 5.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 2.5%

LQDA stock opened at $34.78 on Friday. The stock’s fifty day simple moving average is $61.21 and its two-hundred day simple moving average is $61.73. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a 1-year low of $21.94 and a 1-year high of $93.61. The stock has a market cap of $3.11 billion, a P/E ratio of 24.77 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter last year, the company earned ($0.49) EPS. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. Analysts expect that Liquidia Corporation will post 2.05 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in Liquidia in the second quarter worth $29,694,000. Bank of America Corp DE raised its stake in shares of Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after buying an additional 360,372 shares during the period. Capricorn Fund Managers Ltd bought a new stake in shares of Liquidia in the first quarter valued at $9,337,000. Eversept Partners LP lifted its position in shares of Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after buying an additional 167,949 shares during the last quarter. Finally, Seven Fleet Capital Management LP lifted its position in shares of Liquidia by 124.5% during the 1st quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after buying an additional 113,609 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Analysts Set New Price Targets

Several equities analysts recently weighed in on LQDA shares. Weiss Ratings upgraded shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Raymond James Financial restated an “outperform” rating on shares of Liquidia in a report on Thursday, October 8th. HC Wainwright lifted their price objective on shares of Liquidia from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday. Lifesci Capital upgraded shares of Liquidia from a “market perform” rating to an “outperform” rating and set a $59.00 target price on the stock in a research note on Wednesday. Finally, Piper Sandler set a $129.00 target price on shares of Liquidia in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $72.85.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).